Deal snapshot: AbbVie joins peers Merck & Co., Roche and Pfizer with a TL1A-targeted antibody for potential therapy in inflammatory bowel disease, paying $150m up front.
Who: AbbVie/FutureGen
What: AbbVie has licensed global development and commercialization rights to a preclinical TL1A-targeting antibody for development in inflammatory bowel disease...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.
The total deal value of GLP-1-associated assets globally this year is already double that of the previous two years combined, with China-originated assets accounting for a substantial majority.
The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.
Deal Snapshot: Skyhawk raised its first seed funding in 2018 and has funded its operations primarily through partnering fees to date, including its latest agreement with Merck KGaA.
The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.
The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.
Pfizer showed how to come out on top with investors during earnings season. Post strong sales growth – and avoid mentioning tariffs, most favored nation pricing or Medicare modernization impacts.
